The Lancet Diabetes & Endocrinology
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial
Randomised trial in 242 peopleInterventions
44 weeks, double-blind, placebo-controlled, multicentre, registered NCT06041217
The paper
Chinese Academy of Medical Sciences & Peking Union Medical College; Northwestern University
The Lancet Diabetes & Endocrinology, 10 Aug 2026
